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Abstract
Chronic spontaneous urticaria (CSU) is defined as the spontaneous development of itchy hives and/or angioedema due to known
or unknown causes that last for at least 6 weeks. At any given time, CSU is believed to affect 0.5–1% of the global population.
Omalizumab (a recombinant, humanized anti-immunoglobulin-E antibody) is the only approved treatment for antihistamine
refractory CSU. However, ~ 30% of patients remain symptomatic at licensed doses of omalizumab 150 mg and 300 mg, even
after a treatment period of over 6 months. In the recent years, there have been several studies on updosing of the drug, suggesting
that the individualized approach for urticaria treatment with omalizumab is useful. In this article, we provide an overview of these
studies and the real-world data on omalizumab updosing as it became necessary to obtain complete CSU symptom control in a
proportion of patients. Published observational studies (from June 2003 to October 2019) on the updosing of omalizumab in CSU
were identified using PubMed and Ovid databases. Reports mainly show that updosing/dose adjustment evaluated with the
assessment of disease activity (Urticaria Activity Score) and control (Urticaria Control Test) achieves better clinical response to
omalizumab with a good safety profile in a pool of patients with CSU. These real-world data will provide an overview of
updosing of omalizumab in CSU and aid in setting informed clinical practice treatment expectations.
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Introduction
Chronic spontaneous urticaria (CSU), a subgroup of chronic
urticaria, is defined as the spontaneous daily, or almost daily,
occurrence of itchy hives (wheals), angioedema, or both, last-
ing for 6 weeks or more, with no apparent external trigger [1].
CSU presents a major burden of disease for patients and soci-
ety with a significantly diminished quality of life [2, 3]. The
estimated lifetime point prevalence of CSU is approximately
0.5–1% and nearly 60% of patients with CSU continue to
have the disease despite treatment with antihistamines at the
licensed dose [4–6]. Approximately 33–67% of CSU cases
have both hives and associated angioedema [7–9]. A recent
investigation looking at differences in physician and patient
reporting of angioedema showed that in 40% of inadequately
controlled CSU patients angioedema are reported by both
physicians and patients, but additionally, almost every third
patient reported about occurrence of angioedema while the
physician did not [10].
Much progress has been made recently to delineate the
underlying mechanisms of CSU and the pathogenesis therein,
and to use this understanding to develop better treatment op-
tions including immunoglobulin E (IgE)–targeted therapies,
which show benefit in patients [11, 12]. The EAACI/
GA2LEN/EDF/WAO guidelines recommend following a
stepwise approach to treat urticaria (Fig. 1) [1]. Treatment
with second-generation H1-antihistamines (H1-AHs) are the
mainstay of symptomatic therapy of CSU, with treatment in
licensed standard dosing as first-line, and updosing to up to
four times the recommended standard dosing as the second-
line treatment. The guideline recommended third-line therapy
which is the use of omalizumab as third-line add-on therapy to
H1-AHs, if an inadequate response to H1-AHs is observed
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after 2–4 weeks (or earlier if symptoms are intolerable).
Patients who remain inadequately controlled with
omalizumab after 6 months (or earlier if symptoms are intol-
erable) are recommended to receive add-on therapy with cy-
closporin A as a fourth-line agent.
Omalizumab (a recombinant, humanized anti-IgE antibody)
is an effective and well-tolerated treatment option for CSU and
the first drug approved for use in patients with CSU who re-
main symptomatic despite H1-AH treatment. Omalizumab is
shown to be safe and effective across randomized placebo-
controlled trials [13–15] and several real-world studies
[16–20], with a total patient exposure of 1,328,183 patient
years (Novartis data on file, Dec 2019). Omalizumab binds
IgE and rapidly reduces levels of free IgE by > 90%, resulting
in a subsequent reduction of FcεRI, the high affinity IgE re-
ceptor, on blood basophils andmast cells in the skin [21]. Both
of these mechanisms are thought to importantly contribute to
the efficacy of omalizumab in urticaria [22]. Additional modes
of action of omalizumab may exist in urticaria and further
research will be necessary to fully clarify the potential of
omalizumab in CSU [23]. The definition of response to treat-
ment in CSU differs between clinical trials, real-world studies
and daily practice of individual physicians globally [24], and,
therefore, the response to treatment in CSU also depends upon
how it is measured [25]. Commonly used categories for com-
plete and well-controlled disease activity for CSU include
Urticaria Activity Score (UAS) over 7 days (UAS7) of 0 and
of ≤ 6 respectively. Omalizumab non-responders to treatment
are generally considered to be those patients whose baseline
UAS7 remains unchanged after treatment or who continue to
present a UAS7 > 16 after six doses of omalizumab at 300 mg
every 4 weeks. Partial responders are often defined by a reduc-
tion of the UAS7 by at least 30%, but by less than 90% or by
patients showing a UAS7 > 6 but with an improvement in
UAS7 as compared with baseline [25]. Using the Urticaria
Control Test (UCT), the cutoff values for “controlled disease”
is ≥ 12 which is often considered as a complete response to
treatment (complete control = 16, controlled urticaria ≥ 12, no
control < 12) [25]. As per the current EAACI/GA2LEN/EDF/
WAO guideline, the third line of treatment is recommended for
the partial and non-responders to updosed AH treatment [24].
The licensed dose of omalizumab is 300 mg in Europe and
either 150 mg or 300mg in the USA by subcutaneous injection
every 4 weeks [26]. Some reports have shown examples of the
optimization of omalizumab treatment in patients who show
inadequate response by increasing the dose or decreasing the
dosing intervals [27]; a more flexible treatment regimen rather
than a constant regimen including shortening dosing interval or
augmenting dose based on the patient’s symptoms is also like-
ly to provide better symptom control [28, 29]. Although there
is currently no algorithm for the individualized management of
omalizumab treatment that is agreed on, treatment algorithms
based on specific response profiles of patients refractory to
AHs have been proposed to facilitate clinical management of
omalizumab and enable clinicians to assess therapeutic strate-
gy [2, 30, 31]. The aim of this article is to provide a summary
of the published real-world evidences for the updosing of
omalizumab in the treatment of CSU.
Overview on Omalizumab
Omalizumab is a recombinant humanized IgG1 monoclonal
antibody that binds to IgE-specific epitopes within the C3
(FcεRI binding) region of the IgE molecule, with low immu-
nogenicity, that inhibits binding of IgE to FcεRI on the surface
of mast cells and basophils [32–34]. On continued therapy,
omalizumab is associated with downregulation of cell surface
IgE receptors, further preventing IgE-mediated histamine re-
lease and inflammation.
Omalizumab in the Treatment of Refractory
CSU
Positive results from investigator-reported use of omalizumab
for chronic urticaria provided an impetus for therapeutic
Fig. 1 EAACI/GA2LEN/EDF/WAO International Guideline:
recommended treatment algorithm for urticaria. Short course (maximum
of 10 days) of corticosteroids may also be used at all times if
exacerbations demand this. EAACI, European Academy of Allergology
and Clinical Immunology; EDF, European Dermatology Forum;
GA2LEN, Global Allergy and Asthma European Network; H1-AH, H1
antihistamine; WAO, World Allergy Organization
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treatment in CSU. Successful use of omalizumab in chronic
urticaria began to appear in the literature as early as 2006 as
case reports [35, 36]. The first controlled clinical trials in
chronic spontaneous urticaria followed some years later and
included the X-CUISITE trial [37] which showed a high effi-
cacy of omalizumab in patients with CSU pre-selected for the
presence of anti-thyroid peroxidase-specific IgE autoanti-
bodies [37, 38] and theMYSTIQUE study [39] which showed
improvement in CSU symptoms with omalizumab 300 mg
and formed the basis of further investigations of efficacy and
safety of omalizumab in CSU at this particular dose. Overall,
there is much evidence for the efficacy and safety of
omalizumab and treatment with 300 mg omalizumab every
4 weeks in patients with CSU [40]. Clinical trials for treatment
of CSU with omalizumab generally provide data for up to
6 months; there are ongoing trials with omalizumab treatment
for up to 1 year and for re-treatment effectiveness.
Literature Search Methodology
A literature search was performed in PubMed and Ovid (from
June 2003 to October 2019) for the identification of relevant
studies on the updosing of omalizumab in CSU. The following
search terms were used: “omalizumab” OR “omalizumab 450
mg” OR “omalizumab 600 mg” and “chronic spontaneous
urticaria” OR “chronic idiopathic urticaria” OR “urticaria”
OR “angioedema” AND “real-world evidence” AND/OR
“updosing.” The search was also restricted to English language
and studies in humans. Out of the total 87 hits obtained from
the search, 17 publications with omalizumab updosing were
identified. Of these, nine publications were finally included in
the review. Publications on inter-dose updosing from 150 to
300 mg were excluded. Reference lists of the articles included
were manually searched for additional relevant studies.
Real-World Evidence of Omalizumab
Treatment and Updosing in CSU
Several studies from real-life clinical practice have reported
the safety and efficacy of omalizumab at approved dosing. In a
systematic review of 84 publications, Bernstein et al. [41]
reported the real-world effectiveness of omalizumab for treat-
ment of CSU. The most common initiation dose was 300 mg
(in 62.7% of patients), whereas 34.5% of patients received
150 mg and 2.8% received other regimens [41]. The most
common dosing frequency (83.9%) was every 4 weeks.
There is also much evidence on the long-term effectiveness
and safety, including long-term omalizumab treatment from 1
to 5 years or longer [42–44]. Long-term outcomes in a real-
world study from a large cohort of patients in the USA asso-
ciated with omalizumab 300 mg use were improvements in
disease control, disease course, and patient-reported symp-
toms that were observed at month 6 and continued beyond
24 months, particularly when AHs alone failed to control
symptoms [45]. Across real-world settings, treatment with
omalizumab was thus associated with improved clinical re-
sponse and clinical improvement [46].
Despite our understanding of the long-term treatment of
CSU, it is known that only a minority of patients have symp-
tom control with standard-dosed H1-AH treatment. Updosing
of second-generation AHs as recommended by the EAACI/
GA2LEN/EDF/WAO urticaria guideline as second-line thera-
py can improve response, but many patients remain symptom-
atic. Although omalizumab in licensed dosing has been prov-
en to be effective in H1-AH refractory patients, there are pa-
tients who do not achieve complete control. Here, we
reviewed the published evidence for the use and safety of
updosing omalizumab from the standard monthly 300 mg
dose to higher doses of monthly 450 mg or 600 mg.
From the first report in 2014 by Fiorino et al. [27] in Italy to
the most recent report in 2019 from Aghdam et al. [47] in the
Netherlands, there have been a growing number of publica-
tions reporting real-world evidence for updosing of
omalizumab in CSU (Table 1).
Fiorino et al. [27] reported a case for the long-term treat-
ment of refractory severe CSU by omalizumab with a
UAS7 > 38. The patient was not responding to omalizumab
300 mg for 9 months and achieved complete symptom control
after updosing to the higher dose of 450 mg/month.
Metz et al. [17] from Germany published a retrospective
analysis of 30 patients with CSU not sufficiently treated with
updosed H1-AH. Complete symptom control and remission
of their symptoms (reduction of 90% or more in UAS7) was
observed in 25 of 30 (83%) patients, without the requirement
of any other drugs after the first treatment with omalizumab.
Among 25 patients who achieved complete remission, one
patient was updosed from 150 to 300 mg/3 weeks. In a further
5 (of the 30) patients, the minimum effective dose of
omalizumab was 300 mg every 3 or 4 weeks. Two of these
patients showed significant improvement when updosed from
150 to 450 mg every 4 weeks. The findings suggest that pa-
tients who may not respond to omalizumab show complete
response upon updosing.
Barron et al. [48] from Canada reported a prospective anal-
ysis of 149 patients refractory to treatment of CSU who were
treated with omalizumab 150mg every 4 weeks. The dose and
dose interval of omalizumab was adjusted based on UAS and
physician assessment. A total of 21 patients were updosed
with omalizumab (two patients updosed to 375 mg, ten pa-
tients to 450 mg, and nine patients to 600 mg). From the total
149 patients observed, 52% achieved complete remission,
29% showed significant improvement, and 17% were refrac-
tory. However, the analysis did not consider the updosed pa-
tients separately.
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Asher et al. [49] from Israel reported evidence from real-
life experience on the beneficial effects of high-dose (450 mg
monthly) omalizumab for 50 patients with severe, unrespon-
sive CSU who did not respond to the standard 300 mgmonth-
ly omalizumab dose (Table 2). Response to the starting dose
of omalizumab 300 mg was complete in 30 (60%), partial in
15 (30%), and failed in five (10%) patients. Patients who
showed partial response/failed to respond to 6 or more
omalizumab injections of 300 mg dose, improved with
updosing to 450 mg; of the nine patients who were updosed
to omalizumab 450 mg, only one patient failed to show a
response to the higher dose; while 8 patients improved signif-
icantly. The mean time to response to the higher dose in these
patients was 2.6 ± 0.9 months. A significant decrease in the
UAS7 from 20 ± 9 to 7 ± 10 (P = 0.002) following
omalizumab treatment was reported in the updosed patients
(Table 2).
Vadasz et al. [50] from Israel reported real-life experiences
of 280 patients, where updosing omalizumab from 300 to
450 mg in 78 patients was significantly beneficial in 64.1%
of patients (Table 2). The usefulness of increasing the dose
above 300 mg was carefully assessed in this retrospective
study for a large group of patients with refractory CSU.
After 12 weeks of therapy, response was defined as well-
controlled if improvement was > 80% from baseline (urticaria
between 6 and 18 months; UAS7 12–18 points); 60–70%, fair
response; 40–50%, weak response; and < 30%, failure. Weak
responders and treatment failures had long-lasting urticaria, of
24–60 months, and UAS7 between 20 and 32 points. While
fair responders continued only on AHs, weak responders re-
quired short courses of steroids. The dosage of omalizumab
was increased from 300 to 450 mg after 3 months if the re-
sponse to therapy was weak; further beneficial effect was seen
in 64.1% (50/78) of patients with an increase to omalizumab
450 mg.
Kocatürk et al. [51], in a retrospective analysis of patients
treated with omalizumab for CSU, proposed a protocol for
updosing patients from two urticaria centers from Istanbul,
Turkey, and Barcelona, Spain. From a total of 92 patients
enrolled in Istanbul, 81 were treated with omalizumab
300 mg while 11 received omalizumab 600 mg. Patients
who did not respond to omalizumab 300 mg achieved symp-
tom control after directly being updosed to 600 mg. Response
to updosing occurred in 8/11 patients (72.7%) who achieved a
Table 2 Proportion of patients with chronic spontaneous urticaria achieving complete or partial response on updosing omalizumab from 300 to 450 or
600 mg every 4 weeks
Study Updosed to 450 mg Updosed to 600 mg Efficacy parameter (UAS7/UCT) Complete/partial response, %




17 11 UCT ≥ 12 and UAS7 ≤ 6 64.3 (n = 18)
11 UCT ≥ 12 72.7 (n = 8)
Vadasz et al. 78 64.1 (n = 50)
Curto-Barredo et al. 79 UAS7 ≤ 6 75.0 (n = 59)/25.0 (n = 20)
Salman et al. 13 UCT ≥ 12 and UAS7 ≤ 6 46.2 (n = 6)/23.1 (n = 3)
Aghdam et al. 11 33 UCT ≥ 12 and UAS7 ≤ 6 32.0 (n = 14)/30.0 (n = 13)
UAS7 Urticaria Activity Score over 7 days; UCT, Urticaria Control Test
Table 1 List of all studies
showing omalizumab updosing in
chronic spontaneous urticaria
Author (year) Country Total number
of patients, N
Updose of omalizumab
Fiorino et al. (2014) Italy 2 450 mg/4 weeks
Metz et al. (2014) Germany 30 300 mg/4 or 3 weeks; 450 mg/4 weeks
Barron et al. (2017) Canada 149 450 mg/4 weeks; 600 mg/4 weeks
Asher et al. (2017) Portugal 50 450 mg/4 weeks
Vadasz et al. (2017) Israel 280 450 mg/4 weeks
Kocatürk et al. (2018) Turkey 92 450 mg/4 weeks;
Spain 80 600 mg/4 weeks
Curto-Barredo et al. (2018) Spain 286 450 mg/4 weeks; 600 mg/4 weeks
Salman et al. (2019) Turkey 72 450 mg/4 weeks
Aghdam et al. (2019) Netherlands 166 450 mg/4 weeks; 600 mg/4 or 2 weeks
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UCT score of ≥ 12 at week 12 of updosing (Table 2). From a
total of 80 patients enrolled at the center in Barcelona, a step-
wise dosing regimen was preferred, starting with 450 mg and
updosed to 600 mg if there was no response. Urticaria control
was achieved by 76.4% (13/17) of patients treated with
omalizumab 450 mg and by 45.4% (5/11) of patients given
600 mg. The stepwise approach was thus recommended for
patients with CSU starting from 450 mg and updosing to
600 mg who do not respond nor partially respond to 300 mg
of omalizumab after 3–6 months of treatment. Updosing was
required more often in patients with a body mass index
(BMI) > 30 kg/m2 and with lower UCT scores at the baseline.
Curto-Barredo et al. [52] from Spain, in a recent observa-
tional multicentre study, showed that upon updosing of
omalizumab in 80% of partial or non-responders (of 286 pa-
tients with CSU treated with omalizumab 300 mg every
4 weeks), 75% of patients achieved UAS7 ≤ 6 and disease
control. Fifty-five percent of these patients were updosed to
450 mg every 4 weeks; 20% of patients who had received
omalizumab 450 mg every 4 weeks were further updosed to
600 mg every 4 weeks. Patients with CSU were updosed with
omalizumab if they were considered non-responder to
standard-dosed omalizumab treatment. Here, non-response
was defined as patients having a UAS7 > 6.
It was shown in a bivariate analysis that 41% of the high-
dose (450–600 mg/4 weeks) versus 21% of licensed-dose re-
sponders (300 mg/4 weeks) frequently used cyclosporin A
immediately before start of the anti-IgE therapy. In the multi-
variate analysis, patients with BMI ≥ 30 kg/m2 were associat-
ed with updosed omalizumab (odds ratio 1.14; P = 0.004) and
a predicted likelihood of greater success with omalizumab
treatment in these patients. The variables included in the anal-
ysis were baseline once-daily UAS7, inducible urticaria, an-
gioedema, sex, age, BMI, total immunoglobulin (Ig) E, d-di-
mer, and previous immunosuppressive treatments. Likewise,
patients aged > 57 years old showed a significant association
with omalizumab updosing (odds ratio 1.038; P = 0.013).
Salman et al. [53] reported the effectiveness and safety of
omalizumab 450 mg in a retrospective cohort study of 72
patients treated with omalizumab 300 mg and 450 mg. Of
13 patients with CSU who were unresponsive to omalizumab
300 mg and updosed to 450 mg, six had complete response
and three had good disease control with a mean UAS7 that
decreased from 18.6 to 5.1 and a mean UCT score that
increased from 8.6 to 12.0. A partial response to
omalizumab updosing was noted in 2 patients, while 2
patients were non-responders. No adverse events were re-
ported during the entire study period. It was of interest to
note that lower baseline total IgE levels were used as a
predictor of non-response to omalizumab and the need
for higher doses. Patients were grouped according to base-
line IgE levels as high or low; updosed patients generally
had lower IgE levels.
Aghdam et al. [47] recently demonstrated that updosing
omalizumab from 300 to 450 mg or 600 mg every 4 weeks
(in 44 of 166 patients) resulted in a clinical benefit in 61% of
these patients who were not responsive to the initial dose of
300 mg. If the treatment response after three doses of
omalizumab 600 mg every 4 weeks was insufficient, the sub-
sequent treatment interval was shortened to 2 weeks.
Omalizumab was discontinued if two consecutive doses of
600 mg at 2-week intervals yielded an insufficient response.
The effects of updosing were examined by comparing disease
activity prior to starting omalizumab treatment and at the end
of the high-dose treatment. UAS7 at the end of the high-dose
treatment was improved compared with UAS7 before dose
increase (median of 20.0 vs 4.3, respectively). The additional
effect of updosing was shown by comparing the effect of
standard dose with the high dose, with improved clinical treat-
ment after updosing observed in 61% of patients; 32% had a
complete response and 30% had a partial response. Patient and
treatment characteristics did not differ significantly between
patients treated with standard-dosed and updosed
omalizumab.
Discussion
The objective of this review article was to summarize the
published real-world evidence on the effects of updosing
omalizumab for the clinical management of patients with
CSUwho do not respond to the licensed dose or the prescribed
initial dose of omalizumab. The results presented in this re-
view article have been extracted from several published re-
ports, and provide comprehensive evidence that omalizumab
updosing can result in improvements in UAS7, UCT, and
quality of life scores in patients who were not responding
sufficiently to standard dose of omalizumab. This report also
highlights evidence suggesting that omalizumab updosing is
associated with complete response rates in up to 60% of pa-
tients with refractory CSU. High dose of omalizumab is
shown to be beneficial in patients with CSU who either failed
or had partial response to the standard 300 mg dose of
omalizumab treatment.
The reports assessed in this article suggest that updosing
omalizumab in patients with no response at any time during
dosing intervals after three doses or with partial response after
6 months of treatment at the maximum licensed dose of
300 mg can be considered. There is also increasing evidence
that updosing to omalizumab 600 mg either directly or with a
stepwise approach starting from 450 mg and then updosing to
600 mg if there is no response after omalizumab treatment
results in better disease control.
In addition, there is some evidence that other factors may
be seen to influence the updosing of omalizumab. Better clin-
ical response with regard to disease severity for instance could
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be achieved by updosing omalizumab along with adjustments
to the frequency of omalizumab treatment. Patients with
higher BMI are more likely to require higher doses of the drug
for treatment and achieve greater success with updosing with
omalizumab. Also, patients previously treated with cyclospor-
in A and older patients (> 57 years of age) who may be non-
responders to the standard dose can be expected to have great-
er success with updosing omalizumab [52]. Patients with low-
er IgE levels are more likely to be non-responders to
omalizumab and therefore required updosing more often than
the patients without [53]. Overall, it was observed that
updosing in suboptimal responders was safe and effective.
Patients receiving updosed omalizumab in general had higher
BMI, lower pre-omalizumab UCT scores, and lower IgE
levels. There was also no particular association with gender,
associated angioedema, baseline UAS7 scores or inducible
urticaria, and increased treatment success rate with updosing.
Omalizumab has a well-established safety profile at higher
doses in severe allergic asthma and has been extensively used
to treat adult and pediatric populations in clinical trials and in
real-world practice [54, 55]. The benefits of omalizumab
updosing reported in the real-world treatment of CSU exceed
those reported in clinical trials, while the real-world safety
profile is similar to that reported in clinical trials. The real-
world treatment setting offers benefit to a heterogeneous pop-
ulation of patients affected by CSU and real-life data on their
safety and efficacy profiles. The experiences on the use of
doses higher than the licensed dose of omalizumab 300 mg
provide support to recommend these higher doses for patients
who are partial/non-responders and refractory to treatment.
One of the current limitations with omalizumab treatment in
patients with CSU is the fixed dosing schedule without op-
tions to adapt the therapy to individual patients. Dose optimi-
zation with omalizumab with the potential for updosing in
patients not achieving complete remission is shown to provide
clinical benefit in a considerable number of patients. These
real-world data will provide an overview of updosing of
omalizumab in CSU and aid in setting informed clinical prac-
tice treatment expectations.
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